Gilead Sciences Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five decreased by 50.9% to $979.00M in Q1 2026 compared to the prior quarter.
An increase indicates a shift toward longer-duration assets, potentially to capture higher yields in a stable interest rate environment.
This represents the fair value of available-for-sale debt securities that have maturity dates falling between one and fi...
Commonly disclosed in the notes to financial statements for companies with substantial investment portfolios.
other_available_for_sale_securities_debt_maturities_afte_540252| Q2 '21 | Q3 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q2 '25 | Q3 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $814.00M | $1.08B | $1.40B | $1.31B | $1.27B | $1.31B | $1.31B | $1.15B | $1.91B | $1.99B | $979.00M |
| QoQ Change | — | +32.1% | +30.0% | -6.0% | -3.4% | +3.2% | +0.4% | -12.6% | +66.2% | +4.6% | -50.9% |
| YoY Change | — | — | — | +61.3% | +18.0% | -6.4% | +0.0% | -9.5% | — | — | — |